Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology, Orphans Dominate Japan Fiscal 2018 Approvals

Executive Summary

Oncology again dominated new drug approvals in Japan last fiscal year, when expedited and special review pathways also played a major role in ensuring early access to new therapies.

Advertisement

Related Content

Legal Challenge To First Japan Rituxan Biosimilar Dismissed
Japan Approvals Include World-First For Skyrizi, Kymriah As Asia's First CAR-T
PMDA Chief Defends Japan Spinal Cord Therapy Approval
Japan’s Conditional Approval System Passes Test With Global First Lorlatinib Nod
First Approval Globally For Gilteritinib, In Japan For AML

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125484

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel